DrugPatentWatch Database Preview
Patent: 6,177,074
» See Plans and Pricing
Summary for Patent: 6,177,074
| Title: | Polyethylene glycol modified interferon therapy |
| Abstract: | A method comprising administering a PEG.sub.12000 -IFN alpha conjugate to an individual afflicted with a viral infection susceptible of treatment with interferon alpha, preferably chronic hepatitis C, is disclosed. |
| Inventor(s): | Glue; Paul (Flemington, NJ), Cutler; David L. (Morristown, NJ), Affrime; Melton B. (Flemington, NJ) |
| Assignee: | Schering Corporation (Kenilworth, NJ) |
| Application Number: | 09/281,401 |
| Patent Claims: | see list of patent claims |
Details for Patent 6,177,074
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Schering | SYLATRON | peginterferon alfa-2b | VIAL | 103949 | 011 | 2001-01-19 | Start Trial | Schering Corporation (Kenilworth, NJ) | 2015-11-02 | RX | Orphan | company |
| Schering | SYLATRON | peginterferon alfa-2b | VIAL | 103949 | 010 | 2001-01-19 | Start Trial | Schering Corporation (Kenilworth, NJ) | 2015-11-02 | RX | Orphan | company |
| Schering | SYLATRON | peginterferon alfa-2b | VIAL | 103949 | 009 | 2001-01-19 | Start Trial | Schering Corporation (Kenilworth, NJ) | 2015-11-02 | RX | Orphan | company |
| Schering | PEGINTRON | peginterferon alfa-2b | SYRINGE | 103949 | 008 | 2001-01-19 | Start Trial | Schering Corporation (Kenilworth, NJ) | 2015-11-02 | RX | Orphan | company |
| Schering | PEGINTRON | peginterferon alfa-2b | SYRINGE | 103949 | 007 | 2001-01-19 | Start Trial | Schering Corporation (Kenilworth, NJ) | 2015-11-02 | RX | Orphan | company |
| Schering | PEGINTRON | peginterferon alfa-2b | SYRINGE | 103949 | 006 | 2001-01-19 | Start Trial | Schering Corporation (Kenilworth, NJ) | 2015-11-02 | RX | Orphan | company |
| Schering | PEGINTRON | peginterferon alfa-2b | SYRINGE | 103949 | 005 | 2001-01-19 | Start Trial | Schering Corporation (Kenilworth, NJ) | 2015-11-02 | RX | Orphan | company |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 6,177,074
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 983543 | Start Trial |
| World Intellectual Property Organization (WIPO) | 9716204 | Start Trial |
| World Intellectual Property Organization (WIPO) | 9848840 | Start Trial |
| United States of America | 5908621 | Start Trial |
| United States of America | 6461605 | Start Trial |
| United States of America | 6524570 | Start Trial |
| Slovakia | 149199 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
